Introduction
============

Diabetes mellitus (shortened as diabetes) is a class of diseases where an individual cannot properly maintain plasma glucose levels. There are two main types of diabetes, type 1 and type 2. Type 1 diabetes is characterized by a lack of insulin due to loss of beta cells in the pancreatic islets of Langerhans, whereas type 2 diabetes is typified by a loss of response to insulin. Type 2 diabetes progresses through two stages. First there is a loss of target tissue insulin action (termed insulin resistance) that then results in increased insulin production (hyperinsulinemia). Eventually the second stage is reached when the islets of Langerhans cannot maintain such a high level of insulin production, and "pancreatic exhaustion" sets in causing insulin production to cease. Although the diseases have unique etiologies, several long-term complications are associated with both types of diabetes. Intensive treatment of hyperglycemia significantly prevents diabetic complications ([@b12-btt-2-441]), but glycemic control does not offer sufficient protection from the development of complications.

Besides hyperglycemia, other causal factors appear to contribute to the development of diabetic complications. One such factor is the proinsulin connecting peptide, C-peptide. C-peptide is a cleavage product of insulin synthesis created in the pancreas as part of insulin production, and is released into the circulation with insulin. The average physiological blood concentrations of C-peptide are in the low nM levels in healthy individuals ([@b82-btt-2-441]). When, as in type 1 diabetes and late type 2 diabetes, insulin synthesis is impaired, synthesis of C-peptide is similarly impaired. Exogenous C-peptide has been shown to improve the function of many tissues commonly affected by diabetes complications ([@b61-btt-2-441]; [@b37-btt-2-441]; [@b9-btt-2-441]; Sima and Li 2006), a development supported by the fact that pancreatic and islet of Langerhans transplantation, restoring not only insulin secretion, but also secretion of C-peptide, will prevent and even reverse diabetic complications ([@b16-btt-2-441], [@b17-btt-2-441], [@b18-btt-2-441], [@b19-btt-2-441]; [@b57-btt-2-441]; [@b103-btt-2-441]). Hence, C-peptide deficiency has successively emerged as a possible mechanism for the development of the disproportionate burden of complications affecting insulinopenic diabetes patients. In this paper, some of the beneficial renal and vascular effects of C-peptide are reviewed, as well as the current knowledge regarding C-peptide-mediated molecular mechanisms.

Beneficial effects of C-peptide
===============================

Circulatory benefits
--------------------

It has long been known that diabetes mellitus patients suffer an increased risk of developing, as well as accelerating atherosclerosis -- the principal cause of heart attack, stroke and gangrene of the extremities ([@b8-btt-2-441]). Microangiopathy, atherosclerosis, and abnormalities in small vessel function significantly contribute to the development of diabetes-induced morbidity ([@b34-btt-2-441]). During the development of atherosclerosis, pathological proliferation and migration of vascular smooth muscle cells are necessary to form atherosclerotic plaques. C-peptide has been shown to prevent vascular dysfunction in diabetic rats ([@b32-btt-2-441]), and to reduce proliferation of smooth muscle cells exposed to high glucose ([@b50-btt-2-441]; [@b10-btt-2-441]), a reduction that may suppress diabetes-induced atherosclerosis. It should be noted that under normoglycemic conditions C-peptide stimulates cultured smooth muscle cell proliferation ([@b98-btt-2-441]).

Effects on nitric oxide and vasodilation
----------------------------------------

More than thirty years ago, impaired circulation, relative tissue hypoxia, and an impaired maximal oxygen uptake were reported in insulinopenic diabetes ([@b14-btt-2-441]). Shortly after induction of diabetes in lambs, coronary vascular resistance is elevated ([@b56-btt-2-441]), and diabetic animals are prone to develop increased total peripheral resistance and hypertension ([@b5-btt-2-441]). Administration of C-peptide restores diabetes-impaired skeletal muscle perfusion ([@b35-btt-2-441]), improves capillary skin red blood cell velocity ([@b21-btt-2-441]), and myocardial blood perfusion ([@b24-btt-2-441]) as well as pancreatic islet arteriole diameter ([@b70-btt-2-441]). In type 2 diabetes, C-peptide concentrations correlate with the presence of coronary artery disease and peripheral vascular disease ([@b87-btt-2-441]). The C-peptide-induced beneficial effects are, however, not restricted to the diabetic state. Surprisingly, in myocardial ischemia-reperfusion, C-peptide has been shown to exert cardioprotective effects through nitric oxide (NO) release ([@b108-btt-2-441]).

Effects on erythrocyte deformability
------------------------------------

When erythrocytes are deformed by the narrow space in the capillaries, they release adenosine triphosphate (ATP) ([@b91-btt-2-441]). The ATP released from the erythrocyte stimulates NO synthesis and release from vascular endo-thelial cells, an event that will regulate vascular resistance and improve oxygenation ([@b92-btt-2-441]). In diabetes, erythrocyte deformability is impaired ([@b7-btt-2-441]) and erythrocyte aggregation increases. The impaired deformability results in increased blood viscosity and decreases capillary blood flow and oxygen availability in the tissue. C-peptide levels have been suggested to positively correlate with erythrocyte deformability ([@b13-btt-2-441]). Decreased membrane sodium, potassium adenosine triphosphatase (Na^+^/K^+^-ATPase) activity in erythrocytes is associated with diabetic complications ([@b74-btt-2-441]; [@b13-btt-2-441]), and there are indications that C-peptide concentrations correlate with erythrocyte Na^+^/K^+^-ATPase activity in type 1 as well as type 2 diabetic subjects ([@b13-btt-2-441]). C-peptide is known to ameliorate the impaired deformability of erythrocytes in blood drawn from insulinopenic diabetic patients, and ouabain-inhibition of this effect suggests that the C-peptide-induced effects on erythrocyte deformability are mediated through restoration of the diabetes-impaired Na^+^/K^+^-ATPase activity ([@b53-btt-2-441]). Recently, it was shown by [@b66-btt-2-441] that in the presence of metal ions, C-peptide promotes the release of ATP from erythrocytes, and that this release is mediated via activation of the GLUT1 transporter.

Renoprotection
==============

Early in the development of diabetic nephropathy, the glomerular filtration rate (GFR) increases. Diabetes-induced glomerular hyperfiltration has been proposed as an independent risk factor for the development of renal complications, and it is well known that C-peptide prevents hyperfiltration as well as renal damage in experimental diabetes. C-peptide reduces glomerular hyperfiltration in diabetic patients, and long-term substitution therapy improves renal function ([@b36-btt-2-441], [@b37-btt-2-441]). In animal models of diabetes mellitus, exogenous C-peptide has been shown to reduce diabetes-induced glomerular hyperfiltration and decrease albuminuria ([@b83-btt-2-441], [@b85-btt-2-441]; [@b30-btt-2-441]; [@b76-btt-2-441]; [@b64-btt-2-441]). Structurally, renal glomerular hypertrophy and mesangial matrix expansion is prevented by C-peptide treatment, and it has been shown by [@b64-btt-2-441] that podocyte collagen gene expression is normalized by C-peptide treatment in a mouse model of type 1 diabetes ([@b83-btt-2-441], [@b85-btt-2-441]).

The rat C-peptide carboxy-terminal penta-fragment EVARQ has been shown to abolish diabetes-induced glo-merular hyperfiltration. C-peptide and the penta-fragment both reduce diabetic hyperfiltration ([@b68-btt-2-441]). Hence, it is possible that the five amino acid sequence of the carboxy-terminal of C-peptide is the sequence, or one of the sequences, mediating the normalizing effect on GFR in these diabetic rats. It is common that proteins have defined functional sites. A fragment of gonadotropin-releasing peptide displays increased activity compared to the intact peptide ([@b86-btt-2-441]; [@b75-btt-2-441]). Similar to C-peptide gastrin, cholecystokinin and osteogenic growth peptide, have active sites in their C-terminal penta-peptides ([@b73-btt-2-441]; [@b107-btt-2-441]; [@b2-btt-2-441]; [@b27-btt-2-441]).

Afferent arteriolar constriction
--------------------------------

The glomerular microcirculation is regulated to a great extent through alterations in the vascular resistance of the afferent and efferent arterioles. In insulinopenic diabetes, afferent diameter is increased ([@b33-btt-2-441]). C-peptide constricts isolated renal afferent arterioles from diabetic mice, but not from normoglycemic animals ([@b69-btt-2-441]). Constriction of the afferent arteriole lowers glomerular filtration pressure and thus decreases GFR. However, C-peptide does not appear to diminish renal blood flow ([@b30-btt-2-441], [@b84-btt-2-441]). Taken together, these results suggest that C-peptide reduces diabetes-induced glomerular hyperfiltration at least partly via constriction of the afferent glomerular arteriole, but with a simultaneous dilation of the efferent arteriole that counterbalances the effect on renal blood flow. It should be noted that efferent dilation and increased afferent vascular tone have also been reported for insulin ([@b39-btt-2-441]).

Tubuloglomerular feedback
-------------------------

It has previously been postulated that diabetic hyperfiltration occurs due to alterations in tubuloglomerular feedback (TGF) ([@b100-btt-2-441]; [@b95-btt-2-441]). TGF is an intrarenal mechanism that stabilizes GFR, and thus the tubular Na^+^-load to match the tubular Na^+^ handling capacity. The anatomical prerequisite for TGF is the return of the tubule to its own glomerulus. These, together with the macula densa (MD) make up the juxtaglomerular apparatus. The MD consists of specialized epithelial cells localized where the returning tubule passes the glomerulus, and constitutes a sensor mechanism for Na^+^ by sensing Cl^--^, which relates to Na^+^ levels. Increased tubular flow rate will increase the tubular NaCl load, which is sensed by the MD, and results in a constriction of the afferent arteriole. However, the afferent constriction caused by C-peptide was demonstrated in isolated arterioles, where the arteriole is not set up with an intact tubulus and thus is independent of TGF. In addition, it was recently shown by Sallstrom' et al that TGF does not mediate diabetes-induced hyperfiltration, since diabetes-induced glomerular hyperfiltration occurs in adenosine A1-receptor-deficient mice known to lack a functional TGF mechanism ([@b81-btt-2-441]). If TGF is not the mediator of diabetic hyperfiltration, it is unlikely that C-peptide would exert its effect on filtration via a TGF-dependent mechanism. Therefore, a possible conclusion is that C-peptide exerts its effect directly on the glomerular afferent arterioles.

Many aspects remain to be investigated
--------------------------------------

Blood flow is differentially affected in the kidney vasculature versus peripheral vasculature in the diabetic state. Multiple studies show normalizing effects of C-peptide on diabetes-impaired blood perfusion and blood cell velocity ([@b21-btt-2-441]; [@b38-btt-2-441]). However, in these studies, C-peptide reverses diabetes-induced decreases in peripheral blood perfusion, whereas in renal vessels C-peptide reverses diabetes-induced increases in blood flow ([@b4-btt-2-441]; [@b102-btt-2-441]; [@b52-btt-2-441]). It remains to be determined whether these beneficial, but seemingly opposing effects of C-peptide reflect tissue-specific mechanisms.

Another aspect of C-peptide as a vasoactive substance is that the vasoconstrictive effect of C-peptide takes considerably longer time to develop compared to well known constrictors such as angiotensin II or norepinephrine ([@b69-btt-2-441]). An explanation of this could be a sequential cascade of intracellular events leading to vasoconstriction. Although C-peptide clearly possesses a reducing effect on diabetic hyperfiltration, there is still no effector, no receptor, and no downstream signalling cascade reported for this phenomenon. So what are possible causes of the effect of C-peptide on hyperfiltration? In the next section we review likely candidates mediating C-peptide's physiological properties.

C-peptide cellular signaling
============================

A putative G protein-coupled receptor
-------------------------------------

The first report of a possible receptor was published in 1986 when rat C-peptide I was found to bind specifically to cultured rat islet tumor B-cells ([@b20-btt-2-441]). Early studies suggested that C-peptide mimics insulin action, but that its action on the renal Na^+^/K^+^-ATPase is completely abolished by pretreatment with pertussis toxin (PTX) ([@b71-btt-2-441]). PTX is an inhibitor of Gα~i/o~ family of heterotrimeric G proteins ([@b42-btt-2-441]; [@b104-btt-2-441]), and has been shown to eliminate nearly all C-peptide signaling activities ([@b77-btt-2-441]; [@b45-btt-2-441]; [@b110-btt-2-441]; [@b1-btt-2-441]; [@b60-btt-2-441]), something that strongly suggests that the putative C-peptide receptor is a seven transmembrane G protein-coupled receptor (GPCR).

Identification of GPCRs is not an easy task, and to date the cell surface receptor(s) for C-peptide remain unknown. However, multiple studies have been conducted via manipulating the ligand--C-peptide ([@b32-btt-2-441]; [@b72-btt-2-441]; [@b77-btt-2-441]). Initially, rat and human C-peptides, but not pig C-peptide, were shown to act like insulin and return elevated glucose-mediated blood flow to normal in two models ([@b32-btt-2-441]). The structure of C-peptide was examined by circular dichroism revealing that human and rat C-peptide begin and end with alpha helical domain linked by a flexible glycine rich domain containing a distinctive proline kink in the middle of the sequence; sadly pig C-peptide was not examined ([@b32-btt-2-441]). Additionally, Ido and colleagues indicated that the reverse sequence, all D amino acids, and the middle glycine rich section had similar effects as full length rat and human C-peptide. It should be noted that if there is a receptor involved, then the D amino acids should be inert. The unexpected data lead the authors to conclude that, contrary to previous studies ([@b71-btt-2-441]), the effects are not receptor dependent and that C-peptide enters cells similar to some bacterial proteins ([@b32-btt-2-441]). Shortly thereafter, activity of the glycine rich region was confirmed when examining renal Na^+^/K^+^-ATPase activity ([@b72-btt-2-441]). The glycine rich region was 20% less effective than full length C-peptide, but interestingly, the last 4 amino acids were only 8% less active than full length C-peptide, and the terminal penta-peptide had slightly greater activity than the full length peptide. Moreover, randomly scrambled C-peptide and the D-amino acid penta-peptide had no effect ([@b72-btt-2-441]). These data indicate that indeed sequence specificity and chirality, an essential component of ligand-receptor interactions, are essential for C-peptide activity.

Binding studies demonstrated that C-peptide specifically binds to human renal tubular cells, fibroblasts from the upper arm, and saphenous vein endothelial cells, but not umbilical cord endothelial cells ([@b77-btt-2-441]). Rigler and colleagues found that the half maximal binding (B~50~) was 0.3 nM and B~max~ = 0.9 nM. Importantly, C-peptide binding was not displaced by all D-amino acid C-peptide, insulin, proinsulin, or insulin like growth factor (IGF) I and II; however, the terminal penta-peptide was as efficient in displacement as full length C-peptide ([@b77-btt-2-441]). These data support the theory that the last 5 amino acids mediate the binding of C-peptide to its receptor and that it has a unique receptor independent of the insulin family of receptors. Lastly, [@b77-btt-2-441] confirmed earlier studies that the majority of the receptor is a Gα~i/o~ coupled receptor via use of PTX. However, there appears to be a small pool of receptors that are PTX insensitive, suggesting that C-peptide either has two receptors or a single GPCR that couples to Gα~i/o~ and another Gα subunit ([@b77-btt-2-441]). More recently, multiple studies have confirmed that the secondary structure of C-peptide is essential for proper signaling ([@b46-btt-2-441]; [@b59-btt-2-441]; [@b98-btt-2-441]), and that the penta-peptide mimics C-peptides effects ([@b110-btt-2-441]). Therefore, the earlier studies by [@b32-btt-2-441] have not been repeated, and it appears that C-peptide does bind to yet unidentified receptors.

Recently, the coupling of the C-peptide receptor to Gα~i~ has been proven examining C-peptide-mediated activation of Gα~i~ ([@b1-btt-2-441]). C-peptide, but not scrambled C-peptide, caused the nonhydrolyzable GTP analogue ^35^S-GTPγS to bind to Gα~i~, indicating that C-peptide activates Gα~i~. Unfortunately no other G-protein was examined in this assay, so it is unknown if the PTX insensitive receptor pool is acting through a different G-protein or a different class of receptors. However, these data prove that stimulation of cells with C-peptide activates Gα~i~.

In contrast to the studies suggesting that C-peptide acts through a GPCR, studies using isolated L6 rat myoblast membranes demonstrated that insulin and C-peptide, but not scrambled C-peptide, increased membrane associated tyrosine kinase activity ([@b23-btt-2-441]). Moreover, C-peptide enhances insulin receptor tyrosine kinase activity, although with very low level of activation. These data allowed for theories to be generated about C-peptide binding to, or merely activating, the insulin receptor. In response to the re-emergent theory that C-peptide binds to the insulin receptor, surface plasma resonance (SPR), a technique that detects protein-protein interactions, was used to show little to no binding of C-peptide to insulin or IGF-I receptors ([@b29-btt-2-441]). Moreover, Henricksson and colleagues demonstrated that insulin, but not C-peptide, activates the glucokinase and insulin promoter. Therefore, although the receptors signal similarly in physiological conditions, the molecular mechanisms are not identical and C-peptide binds to a unique receptor.

In support of the GPCR theory, rhodamine-labeled C-peptide binds to Swiss-3T3 and HEK-293 cells and internalizes in a temperature and PTX dependent mechanism ([@b60-btt-2-441]). Additionally, pre-incubation of C-peptide with a C-peptide antibody or unlabeled C-peptide inhibits rhodamine-labeled C-peptide binding. In order to identify a C-peptide receptor, [@b60-btt-2-441] utilized Biacore sensor chips, SPR, and matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) to identify C-peptide binding partners from HEK-293 cell extracts. Intracellular proteins were found to bind to C-peptide, but although the rhodamine-labeled C-peptide was found to internalize, receptor mediated endocytosis does not expose the ligand to the cytosol. Thus, these data need to be examined further to exclude false positive associations, since the ligand may never be exposed to those proteins unless C-peptide is entering the cells in a nonclassical manner as proposed by [@b32-btt-2-441].

In conclusion, it is clear that C-peptide binds to receptor(s) distinctive of the insulin family of receptors. Additionally, one of the receptors stimulates Gα~i~. Collectively, the data strongly suggest that the receptor is a GPCR, in fact this amount of evidence was sufficient for classifying receptors before the advent of cloning. However, since the receptor is still unknown this is not a definitive conclusion. To further complicate the potential identity of the C-peptide receptor, activators of G-protein signaling (AGS) family of proteins are known to activate Gα~i~ independently of GPCRs ([@b6-btt-2-441]). Therefore the precise nature of the C-peptide receptor cannot be determined from the literature and requires further investigation.

Receptor-mediated signal transduction
=====================================

As mentioned previously, the physiological properties mirror, for the most part, insulin-mediated effects. In fact studies conducted in L6 rat myoblasts indicate that C-peptide signals nearly identically to insulin, except in regard to phosphorylation of Akt ([@b23-btt-2-441]). These data along with the physiological effects of C-peptide were strong contributing factors to the proposal that C-peptide signals through the insulin receptor. In this section we will review the general signaling of C-peptide. However, it must be noted that it has already become evident that there are cell-specific signaling mechanisms. For example, in rat medullary thick ascending limb (mTAL) cells C-peptide causes translocation of protein kinase C (PKC) α, but not PKCδ, ε, or ζ, to the plasma membrane ([@b96-btt-2-441]), and in human renal tubular cells C-peptide causes translocation of PKCδ and ε, but not PKCα, γ, ζ, and θ ([@b110-btt-2-441]). Similar discrepancies have been shown for Akt ([@b23-btt-2-441]; [@b110-btt-2-441]) and the NOS isoforms ([@b47-btt-2-441]; [@b99-btt-2-441]; [@b58-btt-2-441]). Therefore, we will include the cell types when describing the signaling pathways, and synthesize a generic signaling paradigm for C-peptide.

Na^+^/K^+^-ATPase
-----------------

Initial studies demonstrated that C-peptide activates the renal Na^+^/K^+^-ATPase through a PTX and FK-506-dependent mechanism ([@b71-btt-2-441]). FK-506 is a specific inhibitor of calcineurin (also known as protein phosphatase 3 and formerly called protein phosphatase 2B), which has been shown to be involved in activation of Na^+^/K^+^-ATPase ([@b55-btt-2-441]). Importantly, calcineurin is activated by binding to calmodulin after increased intracellular Ca^2+^ levels ([@b49-btt-2-441]) indicating that C-peptide must increase intracellular Ca^2+^ levels. This was confirmed in bovine aortic endothelial cells ([@b99-btt-2-441]). Additionally, extensive studies in human renal tubular cells indicate that the L-type Ca^2+^ channel blockers nifedipine and verapamil, as well as the phospholipase C (PLC) inhibitor U73122 inhibit C-peptide-mediated signaling, thus indicating that the Ca^2+^ entry is through L-type Ca^2+^ channels ([@b110-btt-2-441]). The activation of PLC and Ca^2+^ influx provides a mechanism for C-peptide-mediated activation of classical PKC family members, such as PKCα. In rat mTAL cells C-peptide-mediated Na^+^/K^+^-ATPase activity and phosphorylation of the α-subunit of Na^+^/K^+^-ATPase is blocked by the general PKC inhibitor GF109203X ([@b96-btt-2-441]). Further studies in human renal tubular cells confirm the role of PTX and GF109203X, but also show that phosphorylation of the α-subunit of Na^+^/K^+^-ATPase is blocked by PD98059, a MEK inhibitor ([@b109-btt-2-441]). Furthermore, the C-peptide-mediated phosphorylation of the α-subunit of Na^+^/K^+^-ATPase has been shown to be a threonine residue residing within an ERK consensus site. This suggests that ERK, not PKC, is phosphorylating the Na^+^/K^+^-ATPase ([@b109-btt-2-441]) and that PKC is involved in activating ERK, as described in the next section.

These data collectively suggest that C-peptide activates PLCβ2 through Gβγ subunits associated with Gα~i~ ([@b43-btt-2-441]; [@b106-btt-2-441]), and that C-peptide activates L-type Ca^2+^ channels through Gβγ subunits ([@b105-btt-2-441]). The activation of the L-type Ca^2+^ channel by Gβγ alone is rather minimal and requires phosphatidylinositol 3-kinase (PI3K), which is activated by C-peptide ([@b23-btt-2-441]; [@b45-btt-2-441]; [@b59-btt-2-441]; [@b1-btt-2-441]; [@b98-btt-2-441]), to allow for a full Ca^2+^, transient ([@b105-btt-2-441]). Additionally there is a role for PKC in the Gβγ-mediated activation of L-type Ca^2+^ channels ([@b105-btt-2-441]). Since PKCδ and ε do not require Ca^2+^ for activation they may play a role in enhancing the Ca^2+^ transient since they translocate to the membrane after stimulation with C-peptide ([@b110-btt-2-441]). However, the level of C-peptide-mediated activation of the L-type Ca^2+^ channel was not compared to a positive control, and no experiments examining the mechanism of C-peptide-mediated Ca^2+^ entry into cells has been conducted. Thus it is unknown if PKC and PI3K are needed for C-peptide-mediated activation of L-type Ca^2+^ channels and subsequent PKCα activation. As described in the next section, PI3K is most likely needed for activation of ERK, which in humans is a necessary component of C-peptide-mediated phosphorylation of the α-subunit of Na^+^/K^+^-ATPase ([@b109-btt-2-441]). Further experiments are required to definitively describe the signaling cascade from the C-peptide receptor(s) to Na^+^/K^+^ ATPase; the current model is shown in [Figure 1](#f1-btt-2-441){ref-type="fig"}.

MAPKs
-----

Activation of mitogen-activated protein kinases (MAPKs) is common to many signaling molecules; there are three major MAPK proteins: ERK, p38, and JNK. However, the mechanism of receptor-mediated, especially GPCR-mediated, activation of MAPKs is not uniform and is still contested. C-peptide activates ERK, p38, and JNK, but as detailed below only ERK is consistently shown to be activated by C-peptide.

C-peptide signaling to ERK was first reported in 2001 ([@b23-btt-2-441]; [@b45-btt-2-441]). In Swiss 3T3 fibroblasts [@b45-btt-2-441] demonstrated that C-peptide-mediated phosphorylation of ERK has an EC~50~ = 0.25 ± 0.05 nM, which is in accordance with the B~50~ = 0.3 nM ([@b77-btt-2-441]), and ERK is phosphorylated within 10 min. Additionally, signaling to ERK is completely inhibited by PTX, nearly abolished by GF109203X, and inhibited by 50% by the PI3K inhibitor wortmannin. Thus, indicating that Gα~i~ and PKC mediate C-peptide-dependent phosphorylation of ERK, and that PI3K also has a significant role. [@b23-btt-2-441] demonstrated in L6 rat myoblasts a similar concentration response curve that is bell-shaped and showed no response at 10 nM and higher concentrations of C-peptide. This bell-shaped concentration-response curve is unusual; however, the bell-shaped curve is reported throughout the C-peptide literature. Not all studies with C-peptide result in a bell-shaped curve. For instance, C-peptide stimulation of mouse lung capillary endothelial cells results in a standard sigmoidal activation curve for ERK ([@b46-btt-2-441]). The potential physiological consequences of the bell-shaped curve in regards to diabetes treatment will be discussed in the conclusion.

The studies by [@b46-btt-2-441], [@b47-btt-2-441]) indicate that C-peptide increased the phosphorylation of ERK and p38, but not JNK. These studies were reinforced via kinase assays, and thus are the first conclusive proof that C-peptide activates ERK and p38 ([@b46-btt-2-441]). C-peptide-mediated activation of ERK and p38 was confirmed in rat aortic endothelial cells ([@b47-btt-2-441]). In contrast, in human renal tubular cells C-peptide increases phosphorylation of ERK and JNK, but not p38 ([@b110-btt-2-441]). These and other data suggest that ERK is the primary MAPK activated by C-peptide. Via use of specific inhibitors, Kitamura and colleagues demonstrated that ERK leads to phosphorylation of RSK1, but not MSK1. C-peptide-mediated phosphorylation and activation of RSK1 also occurs in L6 rat myoblasts ([@b23-btt-2-441]). Importantly, RSK1 is downstream of ERK and PDK1, and is involved in multiple signaling cascades including inactivation of glycogen synthase kinase ([@b25-btt-2-441]). Thus C-peptide-mediated activation of ERK may be important in processing glucose.

The most complete C-peptide-mediated signaling to ERK has been worked out in vascular smooth muscle cells. C-peptide-mediated ERK and JNK phosphorylation absolutely requires PLC, L-type Ca^2+^ channels, PKC, and MEK activity ([@b98-btt-2-441]). Furthermore, C-peptide signaling to ERK is significantly reduced by treatment with the src family kinase inhibitor PP2 and the PI3K inhibitor LY294002 ([@b98-btt-2-441]). PP2 is a dirty drug ([@b3-btt-2-441]), however Walcher and colleagues also used siRNA demonstrating that c-src is involved in C-peptide-mediated phos-phorylation of ERK. Additionally, PP2 significantly, but not completely, blocks C-peptide mediated generation of PIP3, indicating that src is involved in the activation of PI3K. Activation of ERK in vascular smooth muscle cells leads to cellular proliferation and increased cyclin D1 expression ([@b98-btt-2-441]).

Collectively the data indicate that C-peptide is a potent stimulant of MAPKs, specifically ERK. Most of the studies have used insulin or PDGF as a positive control and found C-peptide to activate ERK to a much lesser extent; however, how C-peptide acts in comparison to ligands with similarly expressed receptors has not been examined. It is known that the C-peptide receptor(s) are less dense than the insulin receptor ([@b77-btt-2-441]). Although there appears to be tissue specificity as to which MAPKs are activated, in all cases ERK is activated. ERK phosphorylation is a common occurrence for Gα~i~-coupled receptors ([@b54-btt-2-441]), and can occur through multiple pathways including through Gα ([@b28-btt-2-441]) and through Gβγ~i~ ([@b11-btt-2-441]; [@b51-btt-2-441]) activation of PI3K ([@b93-btt-2-441]; [@b26-btt-2-441]; [@b62-btt-2-441]). [@b28-btt-2-441] demonstrate that the Gαi-dependent mechanism is independent of Ras and PI3K, but requires PKC, which may explain the 50% inhibition seen with wortmannin ([@b45-btt-2-441]) and allow for more traditional roles for PKC ([@b89-btt-2-441]) and c-src ([@b63-btt-2-441]) as is eluded to by [@b98-btt-2-441]. These accepted pathways partially unite the disparate C-peptide signaling pathways into one mechanism. However, the precise molecular mechanisms of how ERK is activated remain unknown.

In conclusion, the use of PTX, PI3K, and MEK inhibitors suggest that the mechanism involves the classical Ras-Raf/MEK/ERK cascade that is activated by Gβγ-mediated activation of PI3K. However, this does not account for how PKC and c-src are involved in activating this cascade. Thus, although C-peptide clearly activates ERK through a Gα~i~-mediated mechanism that involves PI3K, the multiple cell types used, lack of standardized experiments across cell types, and lack of a known receptor make it impossible to clearly unite all of the data into a single pathway. Our experience indicates that signaling to ERK is cell type-dependent ([@b15-btt-2-441]). Additionally, the disparities between the phosphorylation of p38 and JNK support the idea that cell type dependent mechanisms are involved in the activation of the MAPKs. Thus, we are hesitant to combine all of the data into one pathway.

NO synthase
-----------

There are three isoforms of nitric oxide synthase (NOS): iNOS, nNOS, and eNOS ([@b65-btt-2-441]). C-peptide has been shown to activate eNOS in rat and bovine aortic endothelial cells ([@b47-btt-2-441]; [@b99-btt-2-441]). Wallerath and colleagues demonstrated that C-peptide rapidly generates cGMP in a concentration-dependent manner. cGMP levels peak within 5 min and by 10 min the levels are similar to baseline levels, which can be attributed to phosphodiesterases degrading the cGMP. Furthermore, [@b99-btt-2-441] indicate that C-peptide-mediated increase in cGMP levels were abrogated by the NOS inhibitor L-NNA and by Ca^2+^ free media. This suggests that eNOS is involved in C-peptide-mediated NO production. C-peptide did not increase eNOS mRNA. In contrast, [@b47-btt-2-441] demonstrated that C-peptide transiently increases eNOS, but not iNOS, and that mRNA levels and eNOS protein levels are increased for up to 6 hours. eNOS expression was blocked by inhibiting gene transcription with actinomycin D and inhibition of MEK. Thus, [@b47-btt-2-441] indicate that the ERK MAPK pathway is important in C-peptide-mediated generation of NO. Additionally, [@b47-btt-2-441] observe NO production utilizing the NO sensitive dye DAF-2. The procedure followed, 3 hours of treatment followed by washing and then exposure to DAF-2 for 1 hour, cannot discriminate between the increased levels of eNOS generating increased basal NO and C-peptide-mediated release of NO. Given that [@b99-btt-2-441] show that C-peptide-mediated production of cGMP occurs within 10 min, the DAF-2 results from Kitamura and colleagues are most likely due to the enhanced eNOS protein levels. Supporting, in part, the study by [@b47-btt-2-441], [@b58-btt-2-441] indicate that 24 hour exposure of human smooth muscle cells to C-peptide increases iNOS and eNOS mRNA and protein levels. Though generally reported to be a stimulator of NOS, C-peptide counteracts diabetes-induced increases in renal eNOS levels ([@b41-btt-2-441]). The seeming contradictions in the data may be due to altered mechanisms in the diabetic state, cell type, or methodology, which is not standard between the studies. In summary, C-peptide, like insulin, is involved in generation of NO through activation of eNOS, but the mechanism is largely unknown.

NF-κB activation and protection of diabetic nephropathy
-------------------------------------------------------

There are a few reports indicating that C-peptide activates nuclear factor κB (NF-κB) ([@b1-btt-2-441]; [@b48-btt-2-441]). In Swiss 3T3 cells inhibition of PKC inhibits NF-κB activation ([@b48-btt-2-441]). In OK cells C-peptide protects against tumor necrosis factor α (TNF-α)-mediated apoptosis through an NF-κB mediated mechanism ([@b1-btt-2-441]). C-peptide-mediated NF-κB activity was ablated by PTX and wortmannin, but not PD98059. [@b1-btt-2-441] also demonstrate that C-peptide increases TRAF2, an NF-κB driven survival gene, and blocks high concentration TNF-α-mediated decreased expression of TRAF2. Together the data indicate that C-peptide may activate NF-κB through a PKC- and PI3K-dependent phosphorylation of IκB that then leads to increased translation of NF-κB driven genes that can inhibit TNF-α-mediated signaling. It should be noted that recent data suggest C-peptide rather reduces NF-κB activation ([@b10-btt-2-441]).

Importantly, TNF-α has been suggested in the pathogenesis of diabetic nephropathy ([@b67-btt-2-441]). Additionally, TNF-α is increased in diabetic nephropathy ([@b40-btt-2-441]) and correlates with urinary protein excretion ([@b67-btt-2-441]). Injection of TNF-α decreases renal function ([@b88-btt-2-441]), and [@b67-btt-2-441] demonstrated that inhibiting TNF-α reduces albuminuria in experimental diabetic rats. Therefore, C-peptide-mediated inhibition of TNF-α-mediated effects in renal cells may have clinical benefits.

Activation of RhoA and physiological consequences
-------------------------------------------------

C-peptide activates the small guanosine triphosphatase (GTPase) RhoA through an unknown mechanism in human renal tubular cells ([@b110-btt-2-441]). Physiologically, Rho-kinase, an effector of RhoA, is known to be responsible for mediating "Ca^2+^-sensitation", a condition where smooth muscle constriction is enhanced in similar or lower levels of Ca^2+^ influx ([@b44-btt-2-441]). Rho-kinase is of particular interest because it plays an important role in mediating vaso-constriction in the kidney ([@b79-btt-2-441]). Additionally, RhoA/Rho-kinase regulates blood flow, GFR, and alters the function and structure of renal tubular epithelial cells and mesangial cells ([@b97-btt-2-441]).

We have previously shown that the Rho-kinase inhibition with Y-27632 prevents the vasoconstrictive effects of C-peptide in isolated afferent arterioles, thus suggesting that C-peptide activates RhoA and consequently Rho-kinase in the renal vasculature ([@b69-btt-2-441]). However, reduction of C-peptide-induced vasoconstriction by inhibition of Rho-kinase does not necessarily imply that C-peptide activates Rho-kinase ([Figure 2](#f2-btt-2-441){ref-type="fig"}). C-peptide is known to increase PKC and MAPKs, both of which are capable of mediating contraction (via CPI-17 and caldesmon, respectively ([@b22-btt-2-441]; [@b101-btt-2-441]; [@b80-btt-2-441]). Additionally, MAPK has been linked to phosphorylation of the regulatory subunit of the myosin light chain in the same location as myosin light chain kinase ([@b78-btt-2-441]). Moreover, Gα~i~-coupled receptors can activate integrin-linked kinase (ILK) through a PI3K-dependent pathway that results in phosphorylation of CPI-17 and the myosin light chain at the same site as myosin light chain kinase ([@b31-btt-2-441]). Since inhibition of Rho-kinase allows for greater myosin phosphatase activity, which in turn will decrease the phosphorylation status of the regulatory subunit of the myosin light chain, it is possible that C-peptide induces phosphorylation of the myosin light chain through one of the aforementioned pathways, and that Y-27632 is only increasing the basal level of myosin phosphatase. Thus, more investigation is warranted into the link between C-peptide and RhoA/Rho-kinase activation in the renal vasculature.

Concluding remarks
==================

Thus far, the results from C-peptide studies display several unexplored research directions and opportunities for novel therapeutic interventions. It is clear that C-peptide possesses beneficial effects on diabetes-induced complications. This is supported by pancreas and islet of Langerhans transplantation in diabetic patients, restoring not only the patients' insulin production, but also production of C-peptide. Thus, large scale clinical trials examining the benefits of C-peptide should be initiated in diabetic patients. In type 1 and stage 2 type 2 diabetes restoring circulating C-peptide is most likely going to be beneficial to the patient. However, the aforementioned bell-shaped concentration response curve may, paradoxically, help potentiate insulin resistance. In many cases mid to high nanomolar concentrations of C-peptide signalled less than low nanomolar concentrations, which could reduce the physiological effect of C-peptide and may explain why the increased levels of C-peptide in phase 1 type 2 diabetics is not beneficial. This apparent paradox must be more fully examined before C-peptide is administered to hyperinsulinemic type 2 diabetic patients. Additionally, if this paradox is physiologically relevant then the level of C-peptide administration would have to be carefully monitored, such as is done with insulin.

Finally, there are multiple basic and clinically relevant questions that remain unanswered. The identity of the receptor is clinically important, and the downstream signalling cascade, as currently known, does not fully explain amelioration of diabetes-induced complications. Further studies should be undertaken, investigating the intracellular effects of C-peptide. If the C-peptide receptor is a GPCR, then an agonist to the receptor can be generated. This is important since C-peptide may not be easily administered to patients, whereas a stable agonist may be able to be supplied as a once a day pill. Similarly, more fully understanding the cellular signaling of C-peptide may lead to novel interventions in diabetes associated diseases, such as nephropathy.

In conclusion, the field of C-peptide biology has accelerated greatly in the last 15 years. It is clear that C-peptide is biologically active, binds to cell surface receptors, and signals in a manner similar but unique from insulin. Physiologically, the effects are in some aspects similar to that of giving insulin to type 1 diabetic patients; however, C-peptide appears to restore insulin-treated type 1 diabetic patients to normal physiology. Given that C-peptide is a hormone co-secreted with insulin, and thus is absent in type 1 diabetes, the beneficial effects of C-peptide are not surprising.
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![Molecular mechanisms of C-peptide-mediated activation of Na^+^/K^+^ ATPase. This cartoon simplifies the signaling cascade resulting in activation of the Na^+^/K^+^ ATPase. Arrows represented signaling cascades. The activation of ERK is not completely understood. For simplicity it drawn with a single arrow from PKCα; however, it is known not to be a direct mechanism. Similarly, the precise role of calcineurin in regulation of the Na^+^/K^+^-ATPase is unknown, and is represented here by a simple arrow. The question mark (**?**) indicates simplified or unknown pathways.\
**Abbreviations:** PLC, phospholipase C; PKCα, protein kinase Cα; ERK, extracellular regulated kinase; CAM, calmodulin.](btt-2-441f1){#f1-btt-2-441}

![Schematic illustrations of sequences of events leading to constriction. This schematic drawing illustrates possible downstream effects of C-peptide.](btt-2-441f2){#f2-btt-2-441}
